Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies
Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies
复制标题
DOI：
10.1007/s00405-016-4227-7
复制
发表时间：
2017-01-01
影响因子：
2.6
通讯作者：
Lill, Claudia
中科院分区：
文献类型：
--
作者：
Kadletz, Lorenz;Aumayr, Klaus;Lill, Claudia
涎腺癌是一种罕见的恶性肿瘤。因此，对唾液腺恶性肿瘤中的生物标志物和癌症干细胞知之甚少。双重皮质醇样激酶1(DCLK1)是一种很有前途的治疗靶点和肿瘤干细胞标记物，主要研究在胰腺癌和结直肠癌中。本研究的目的是探讨DCLK1在大、小涎腺癌中的表达及其对生存的影响。在这项回顾性研究中，我们总共检查了80名患有大小涎腺癌的患者。用抗DCLK1抗体免疫组织化学方法检测DCLK1的表达。此外，我们还评估了DCLK1对总体和无病生存率的影响。66.3%的病例可检测到DCLK1的表达。在大涎腺癌患者中，DCLK1的过度表达与总体生存率和无病生存期的减少有关。无瘤生存率达到统计学意义(p=0.0107)。然而，DCLK1的表达对小涎腺癌患者的生存没有影响。由于肿瘤患者复发疾病的治疗是完全具有挑战性的，DCLK1可能是一个有希望的预后生物标志物，有助于识别大涎腺癌复发的高风险患者。
Salivary gland carcinomas are a rare malignancy. Therefore, little is known about biomarkers and cancer stem cells in salivary gland malignancies. Double cortin-like kinase 1 (DCLK1) is a promising therapeutic target and cancer stem cell marker, predominantly investigated in pancreatic and colorectal cancer. The purpose of this study was to investigate the expression of DCLK1 in major and minor salivary gland carcinomas and its influence on survival. We examined a total of 80 patients with major or minor salivary gland cancer in this retrospective study. Immunohistochemistry with anti-DCLK1 antibody was applied to assess the expression of DCLK1. Moreover, we evaluated the impact of DCLK1 on overall and disease-free survival. DCLK1 expression could be detected in 66.3 % of all examined cases. Overexpression of DCLK1 was associated with reduced overall and disease-free survival in patients with major salivary gland cancer. Disease-free survival reached statistical significance (p = 0.0107). However, expression of DCLK1 had no influence on survival in patients with minor salivary gland cancer. Since treatment of recurrent disease in oncologic patients is utterly challenging, DCLK1 may be a promising prognostic biomarker that helps to identify patients with a high risk for recurrence of major salivary gland carcinoma.